"Peregrine is currently advancing the proprietary exosome-based cancer diagnostic technology, licensed from UT Southwestern Medical Center in July 2016, with the goal of developing an optimized test for further clinical testing."
Well my point was that they make it sound like they have not achieved their goal of having that POC test as of Feb 9th, which still sounds like an early stage of product development..
News 
Market Data 
Discover 
AI
